Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study.

Autor: Minakata D; Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Uchida T; Department of Hematology, Eiju General Hospital, Tokyo, Japan., Nakano A; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine Tokyo, Tokyo, Japan., Takase K; Department of Haematology, Clinical Research Centre, National Hospital Organization Kyushu Medical Centre, Fukuoka, Japan., Tsukada N; Department of Hematology/Oncology, Asahikawa Kosei General Hospital, Asahikawa, Japan., Kosugi H; Department of Hematology, Ogaki Municipal Hospital, Ogaki, Japan., Kawata E; Department of Hematology, Panasonic Health Insurance Organization Matsushita Memorial Hospital, Moriguchi, Japan., Nakane T; Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan., Takahashi H; Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Kanagawa, Japan., Endo T; Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan., Nishiwaki S; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Fujiwara H; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan., Saito AM; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan., Saito TI; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan., Akashi K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan., Matsumura I; Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama, Japan., Mitani K; Department of Hematology and Oncology, Dokkyo Medical University, 880, Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi, 321-0293, Japan. mitanik@dokkyomed.ac.jp.
Jazyk: angličtina
Zdroj: International journal of hematology [Int J Hematol] 2024 Feb; Vol. 119 (2), pp. 183-195. Date of Electronic Publication: 2024 Jan 03.
DOI: 10.1007/s12185-023-03685-w
Abstrakt: The Japanese Society of Hematology performed an observational cross-sectional study to clarify the morbidity, prognosis, and prognostic factors in patients with COVID-19 with hematological diseases (HDs) in Japan. The study included patients with HDs who enrolled in our epidemiological survey and had a COVID-19 diagnosis and a verified outcome of up to 2 months. The primary endpoints were characteristics and short-term prognosis of COVID-19 in patients with HDs. A total of 367 patients from 68 institutes were enrolled over 1 year, and the collected data were analyzed. The median follow-up among survivors was 73 days (range, 1-639 days). The 60-day overall survival (OS) rate was 86.6%. In the multivariate analysis, albumin ≤ 3.3 g/dL and a need for oxygen were independently associated with inferior 60-day OS rates (hazard ratio [HR] 4.026, 95% confidence interval (CI) 1.954-8.294 and HR 14.55, 95% CI 3.378-62.64, respectively), whereas 60-day survival was significantly greater in patients with benign rather than malignant disease (HR 0.095, 95% CI 0.012-0.750). Together, these data suggest that intensive treatment may be necessary for patients with COVID-19 with malignant HDs who have low albumin levels and require oxygen at the time of diagnosis.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: